Cingulate

Cingulate FCF Growth

The Year-over-Year Free Cash Flow Growth of Cingulate (CING) as of Nov 3, 2026 is 6.73 %. In the previous year, Year-over-Year Free Cash Flow Growth was -22.31 % — a change of -130.16% (higher).

FCF Growth

6.73 %

YoY

-130.16%

Last updated:

Year-over-Year Free Cash Flow Growth of Cingulate is 2025 6.73 % . Year-over-Year Free Cash Flow Growth of Cingulate was 2024 -22.31 % . It decreases by -130.16% higher compared to the previous year.

The Cingulate FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2020
31.62 USD
Jan 1, 2021
-55.93 USD
Jan 1, 2022
-42.58 USD
Jan 1, 2023
4.85 USD
Jan 1, 2024
-22.31 USD
Jan 1, 2025
6.73 USD
The Cingulate FCF Growth history
YEARFCF GrowthYoY
6.73 %-130.16%
-22.31 %-560.15%
4.85 %-111.39%
-42.58 %-23.88%
-55.93 %-276.89%
31.62 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

Year-over-Year Free Cash Flow Growth of Cingulate is 6.73 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Cingulate since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Cingulate historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Cingulate

All Key Metrics — Cingulate